Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 219402, 8 pages
http://dx.doi.org/10.1155/2012/219402
Research Article

Quality of Life and Related Dimensions in Cancer Patients Treated with Mistletoe Extract (Iscador): A Meta-Analysis

Center for Integrative Medicine, Faculty of Health, University of Witten/Herdecke, Gerhard-Kienle-Weg 4, 58239 Herdecke, Germany

Received 17 December 2010; Accepted 19 April 2011

Academic Editor: Andrew Scholey

Copyright © 2012 Arndt Büssing et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. B. Bausell, W. L. Lee, and B. M. Berman, “Demographic and health-related correlates of visits to complementary and alternative medical providers,” Medical Care, vol. 39, no. 2, pp. 190–196, 2001. View at Google Scholar · View at Scopus
  2. A. Büssing, Mistletoe. The Genus Viscum, Harwood Academic, Amsterdam, The Netherlands, 2000.
  3. R. Steiner, Geisteswissenschaft und Medizin, Rudolf Steiner, Dornach, Switzerland, 1985.
  4. R. Steiner, “Besprechungen mit praktizierenden Ärzten,” in Physiologisch-therapeutisches auf Grundlage der Geisteswissenschaft, R. Steiner, Ed., pp. 285–301, Rudolf Steiner, Dornach, Switzerland, 1989. View at Google Scholar
  5. A. Büssing, “Mistletoe extracts from an anthroposophical point of view,” in Complementary Oncology. Adjunctive Methods in the Treatment of Cancer, J. Beuth and R. W. Moss , Eds., pp. 197–2006, Thieme, Stuttgart, Germany, 2008. View at Google Scholar
  6. G. S. Kienle, F. Berrino, A. Büssing, E. Portalupi, S. Rosenzweig, and H. Kiene, “Mistletoe in cancer—a systematic review on controlled clinical trials,” European journal of medical research, vol. 8, no. 3, pp. 109–119, 2003. View at Google Scholar · View at Scopus
  7. A. Büssing, “Overview on Viscum album L. products,” in The Genus Viscum, A. Büssing, Ed., pp. 209–221, Harwood Academic, Amsterdam, The Netherlands, 2000. View at Google Scholar
  8. H. Kiene, “Klinische Studien zur Misteltherapie karzinomatöser Erkrankungen. Eine Übersicht,” Therapeuticon, vol. 3, pp. 347–353, 1989. View at Google Scholar
  9. G. S. Kienle and H. Kiene, “Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts,” European Journal of Medical Research, vol. 12, no. 3, pp. 103–119, 2007. View at Google Scholar · View at Scopus
  10. G. S. Kienle and H. Kiene, Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen, Schattauer, Stuttagrt, Germany, 2003.
  11. E. Ernst, K. Schmidt, and M. K. Steuer-Vogt, “Mistletoe for cancer? A systematic review of randomised clinical trials,” International Journal of Cancer, vol. 107, no. 2, pp. 262–267, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Horneber, G. Bueschel, R. Huber, K. Linde, and M. Rostock, “Mistletoe therapy in oncology,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD003297, 2008. View at Google Scholar · View at Scopus
  13. T. Ostermann, C. Raak, and A. Büssing, “Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review,” BMC Cancer, vol. 9, Article ID 451, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Büssing, K. Suzart, and K. Schweizer, “Differences in the apoptosis-inducing properties of Viscum album L. extracts,” Anti-Cancer Drugs, vol. 8, supplement 1, pp. S9–S14, 1997. View at Google Scholar · View at Scopus
  15. A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. D. F. Stroup, J. A. Berlin, S. C. Morton et al., “Meta-analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis of observational studies in epidemiology (MOOSE) group,” The Journal of the American Medical Association, vol. 283, pp. 2008–2012, 2000. View at Google Scholar
  17. D. Moher, D. J. Cook, S. Eastwood, I. Olkin, D. Rennie, and D. F. Stroup, “Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement,” Lancet, vol. 354, no. 9193, pp. 1896–1900, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. J. P. T. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.1 edn, The Cochrane Collaboration, 2008.
  19. F. M. Wolf, Meta-Analysis: Quantitative Methods for Research Synthesis, Sage Publications, Beverly Hills, Calif, USA, 1986.
  20. J. A. C. Sterne and M. Egger, “Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis,” Journal of Clinical Epidemiology, vol. 54, no. 10, pp. 1046–1055, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. S. G. Thompson and S. J. Sharp, “Explaining heterogeneity in meta-analysis: a comparison of methods,” Statistics in Medicine, vol. 18, no. 20, pp. 2693–2708, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis,” Statistics in Medicine, vol. 21, no. 11, pp. 1539–1558, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. J. L. Fleiss, “The statistical basis of meta-analysis,” Statistical Mmethods in Mmedical Research, vol. 2, no. 2, pp. 121–145, 1993. View at Google Scholar · View at Scopus
  24. E. Borrelli, G. Alberti, and J. Shaw, “Evaluation of the quality of life in breast cancer patients undergoing lectin standardized mistletoe therapy,” Minerva Medica, vol. 92, pp. 105–107, 2005. View at Google Scholar
  25. U. Dold, L. Edler, H. C. Mäurer, B. Sakellariou, F. Trendelenburg, and G. Wagner, Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom, Georg Thieme, Stuttgart, Germany, 1991.
  26. R. Grossarth-Maticek, H. Kiene, S. M. Baumgartner, and R. Ziegler, “Use of iscador, an extract of European mistletoe (Viscum Album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study,” Alternative Therapies in Health and Medicine, vol. 7, no. 3, pp. 57–78, 2001. View at Google Scholar · View at Scopus
  27. R. Grossarth-Maticek, H. Kiene, S. M. Baumgartner, and R. Ziegler, “Verlängerung der Überlebenszeit von Krebspatienten unter Misteltherapie (Iscador),” Schweizer Zeitschrift für Ganzheitsmedizin, vol. 13, pp. 217–225, 2001. View at Google Scholar
  28. R. Grossarth-Maticek and R. Ziegler, “Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with mistletoe preparation (Iscador): a re-analysis,” European Journal of Medical Research, vol. 11, no. 11, pp. 485–495, 2006. View at Google Scholar · View at Scopus
  29. R. Grossarth-Maticek and R. Ziegler, “Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador),” Forsch Komplement Med, vol. 13, no. 5, pp. 285–292, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Grossarth-Maticek and R. Ziegler, “Prospective controlled cohort studies on long-term therapy of ovarian cancer patients with mistletoe (Viscum album L.) extracts Iscador,” Arzneimittelforschung, vol. 57, pp. 665–678, 2007. View at Google Scholar
  31. R. Grossarth-Maticek and R. Ziegler, “Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador),” Forsch Komplement Med, vol. 14, no. 3, pp. 140–147, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Grossarth-Maticek and R. Ziegler, “Efficacy and safety of the long-term treatment of melanoma with a mistletoe preparation (Iscador)Wirksamkeit und unbedenklichkeit einer langzeitbehandlung von melanompatienten mit einem mistelpräparat (Iscador),” Schweizerische Zeitschrift fur GanzheitsMedizin, vol. 19, no. 6, pp. 325–332, 2007. View at Google Scholar · View at Scopus
  33. R. Grossarth-Maticek and R. Ziegler, “Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador),” European Journal of Medical Research, vol. 13, no. 3, pp. 107–120, 2008. View at Google Scholar · View at Scopus
  34. C. von Hagens, A. Loewe-Mesch, J. J. Kuehn, U. Abel, and I. Gerhard, “Prospektive kontrollierte nicht randomisierte Machbarkeits-Studie zu einer postoperativen simultanen Mistel-/Chemotherapie bei Patientinnen mit Mammakarzinom—Ergebnisse zu Rekrutier- und Randomisierbarkeit, Immunparametern, Lebensqualität und Verträglichkeit,” in Fortschritte in der Misteltherapie—Aktueller Stand der Forschung und klinische Anwendung, R. Scheer, R. Bauer, H. Becker, V. Fintelmann, F. H. Kemper, and H. Schilcher, Eds., pp. 567–578, Karl und Veronica Carstens-Stiftung, Essen, Germany, 2005. View at Google Scholar
  35. M. Kjaer, “Mistletoe (Iscador) therapy in stage 4 renal adenocarcinoma. A phase 2 study in patients with measurable lung metastases,” Acta Oncologica, vol. 28, no. 4, pp. 489–494, 1989. View at Google Scholar · View at Scopus
  36. M. Kjaer, “Misteltoe therapy of metastasizing kidney cancer. A phase 2 studyMisteltenbehandling af metastaserende nyrecancer. En fase 2 undersøgelse,” Ugeskrift for Laeger, vol. 150, no. 39, pp. 2352–2354, 1988. View at Google Scholar · View at Scopus
  37. W. O. Spitzer, A. J. Dobson, J. Hall et al., “Measuring the quality of life of cancer patients: a concise QL-index for use by physicians,” Journal of Chronic Diseases, vol. 34, pp. 585–597, 1981. View at Google Scholar
  38. N. K. Aaronson, S. Ahmedzai, B. Bergman et al., “The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology,” Journal of the National Cancer Institute, vol. 85, no. 5, pp. 365–376, 1993. View at Google Scholar · View at Scopus
  39. C. C. Schag, R. L. Heinrich, and P. A. Ganz, “Karnofsky performance status revisited: reliability, validity, and guidelines,” Journal of Clinical Oncology, vol. 2, no. 3, pp. 187–193, 1984. View at Google Scholar · View at Scopus
  40. R. Grossarth-Maticek, H. Kiene, S. M. Baumgartner, and R. Ziegler, “Synergieeffekte von Selbst-regulation und Misteltherapie (Iscador) auf die Überlebenszeit bei Krebspatienten,” Schweizerische Zeitschrift fur GanzheitsMedizin, vol. 16, no. 2, pp. 81–89, 2004. View at Google Scholar · View at Scopus
  41. A. Büssing, M. Girke, C. Heckmann, F. Schad, T. Ostermann, and M. Kröz, “Validation of the self regulation questionnaire as a measure of health in quality of life research,” European Journal of Medical Research, vol. 14, no. 5, pp. 223–227, 2009. View at Google Scholar · View at Scopus
  42. P. Németh, T. Hajt, K. Fodor, and P. Perjési, “Difficulties and perspectives of immunomodulatory therapy with mistletoe lectins and standardized mistletoe extracts in evidence-based medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 298972, 6 pages, 2011. View at Publisher · View at Google Scholar
  43. A. Büssing, W. Tröger, C. Stumpf, and M. Schietzel, “Local reactions to treatments with Viscum album L. extracts and their association with T-lymphocyte subsets and quality of life,” Anticancer Research, vol. 28, pp. 1893–1897, 2008. View at Google Scholar
  44. H. C. Diener, C. F. Schorn, U. Bingel, and D. W. Dodick, “The importance of placebo in headache research,” Cephalalgia, vol. 28, no. 10, pp. 1003–1011, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Oeltjenbruns and M. Schäfer, “Clinical significance of the placebo effect,” Anaesthesist, vol. 57, no. 5, pp. 447–463, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. T. J. Kaptchuk, “The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance?” Annals of Internal Medicine, vol. 136, no. 11, pp. 817–825, 2002. View at Google Scholar · View at Scopus